본문 바로가기

Pediatric humoral immune responses and infection risk after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and two-dose vaccination during SARS-CoV-2 omicron BA.5 and BN.1 variants predominance in South Korea

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
FRONTIERS IN IMMUNOLOGY14 · 2023
피인용
Web of Science 6Scopus 6
FWCI (Scopus)
0.45
JCR IF
JCR 2022 7.3
ISSN
1664-3224

저자

  1. Choi, Hyun-Woo제1저자Chonnam Natl Univ Hosp, Dept Lab Med, Gwangju, South Korea
  2. Achangwa, ChiaraKonyang Univ, Coll Med, Dept Prevent Med, Daejeon, South Korea
  3. Park, JoonhongJeonbuk Natl Univ, Dept Lab Med, Med Sch & Hosp, Jeonju, South Korea
  4. 이선민Pusan Natl Univ, Sch Med, Dept Lab Med, Pusan, South Korea
  5. Lee, Nan YoungKyungpook Natl Univ, Sch Med, Dept Clin Pathol, Daegu, South Korea
  6. Jeon, Chae-HyeonChonnam Natl Univ, Med Sch, Res Inst Med Sci, BioMed Sci Grad Program BMSGP, Hwasun, South Korea
  7. Choi, Jeong-HwaChonnam Natl Univ, Med Sch, Res Inst Med Sci, BioMed Sci Grad Program BMSGP, Hwasun, South Korea
  8. Do, Hyun KyungKonyang Univ, Coll Med, Dept Prevent Med, Daejeon, South Korea
  9. Nam, Jeong-HyunKorea Dis Control & Prevent Agcy, Natl Inst Infect Dis, Ctr Vaccine Res, Div Vaccine Clin Res,Natl Inst Hlth, Cheongju, South Korea
  10. Lee, June-WooKorea Dis Control & Prevent Agcy, Natl Inst Infect Dis, Ctr Vaccine Res, Div Vaccine Clin Res,Natl Inst Hlth, Cheongju, South Korea
  11. Kim, ByounggukKorea Dis Control & Prevent Agcy, Natl Inst Infect Dis, Ctr Vaccine Res, Div Vaccine Clin Res,Natl Inst Hlth, Cheongju, South Korea
  12. Ryu, Sukhyun교신저자Konyang Univ, Coll Med, Dept Prevent Med, Daejeon, South Korea
  13. Kee, Seung-Jung교신저자Chonnam Natl Univ Hosp, Dept Lab Med, Gwangju, South Korea

초록

Background: Humoral immune responses and infection risk after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination during the Omicron BA.5 and BN.1 variants predominant period remains unexplored in pediatric population. Methods: We examined anti-spike (anti-S) immunoglobulin G (IgG) responses in a total of 986 children aged 4−18 years who visited outpatient clinics between June 2022 and January 2023, with a history of SARS-CoV-2 infection alone, completed two doses of COVID-19 vaccination alone, vaccine-breakthrough infection (i.e., infection after the single dose of vaccination), and no antigenic exposure. Furthermore, to determine SARS-CoV-2 infection risk, the incidence of newly developed SARS-CoV-2 infection was investigated up to March 2023. Results: The anti-S IgG levels in the ‘vaccine-breakthrough infection’ group exceeded those in the ‘infection alone’ and ‘vaccination alone’ groups (both P <0.01). Furthermore, the ‘vaccination alone’ group experienced more rapid anti-S IgG waning than the ‘infection alone’ and ‘vaccine-breakthrough infection’ groups (both P <0.01). We could not identify newly developed SARS-CoV-2 infection in the ‘vaccine-breakthrough infection’ group. Conclusion: Our findings suggest that hybrid immunity, acquired from SARS-CoV-2 infection and COVID-19 vaccination, was a potentially higher and longer-lasting humoral immune response and protected against SARS-CoV-2 infection in pediatric population during Omicron BA.5 and BN.1 variants predominant.

키워드

antibody responsechildCOVID-19hybrid immunitySARS-CoV-2vaccineANTIBODIESSEROPREVALENCE

식별자

Scopus EID
2-s2.0-85181228404
WoS UID
001134892300001